Correction to: Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants.

Journal

Molecular diagnosis & therapy
ISSN: 1179-2000
Titre abrégé: Mol Diagn Ther
Pays: New Zealand
ID NLM: 101264260

Informations de publication

Date de publication:
Aug 2020
Historique:
pubmed: 24 6 2020
medline: 24 6 2020
entrez: 24 6 2020
Statut: ppublish

Résumé

This article was originally published under a [CC BY NC 4.0] license.

Identifiants

DOI: 10.1007/s40291-020-00479-2 PMID: 32572786 PMC: PMC7363732
pubmed: 32572786
doi: 10.1007/s40291-020-00479-2
pii: 10.1007/s40291-020-00479-2
pmc: PMC7363732
doi:

Types de publication

Published Erratum

Langues

eng

Sous-ensembles de citation

IM

Pagination

505

Subventions

Organisme : Medical Research Council
ID : MR/M009157/1
Pays : United Kingdom

Commentaires et corrections

Type : ErratumFor

Auteurs

Valerie Pestinger (V)

Surgical Research Laboratory, Institute of Cancer and Genomic Sciences, University of Birmingham, Vincent Drive, Birmingham, B15 2TT, UK.

Matthew Smith (M)

Queen Elizabeth Hospital Birmingham, Birmingham, UK.

Toju Sillo (T)

Surgical Research Laboratory, Institute of Cancer and Genomic Sciences, University of Birmingham, Vincent Drive, Birmingham, B15 2TT, UK.

John M Findlay (JM)

Northern Devon Healthcare NHS Trust, Barnstaple, UK.

Jean-Francois Laes (JF)

OncoDNA, Gosselies, Belgium.

Gerald Martin (G)

PierianDx, St. Louis, MO, USA.

Gary Middleton (G)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Phillipe Taniere (P)

Queen Elizabeth Hospital Birmingham, Birmingham, UK.

Andrew D Beggs (AD)

Surgical Research Laboratory, Institute of Cancer and Genomic Sciences, University of Birmingham, Vincent Drive, Birmingham, B15 2TT, UK. a.beggs@bham.ac.uk.
Queen Elizabeth Hospital Birmingham, Birmingham, UK. a.beggs@bham.ac.uk.
ORCID: 0000-0003-0784-2967

Classifications MeSH